ArticlebioRxiv : the preprint server for biology2025
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.
Abstract readPreprint
In one paragraph
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
48 authors.
Carolyn WilliamsonInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Chivonne MoodleyInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Craig A MagaretVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Elena E GiorgiVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Morgane RollandU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Dylan H WestfallVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Anna YsselInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Wenjie DengDepartments of Microbiology, University of Washington, Seattle, WA, USA.
Raabya RossenkhanVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Nonhlanhla N MkhizeNational Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Lennie ChenDepartments of Microbiology, University of Washington, Seattle, WA, USA.
Hong ZhaoDepartments of Microbiology, University of Washington, Seattle, WA, USA.
Tanmoy BhattacharyaTheoretical Division, Los Alamos National Laboratory, Los Alamos, NM, USA.
Alec PankowDepartments of Microbiology, University of Washington, Seattle, WA, USA.
Ben MurrellDepartment of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, Solna 171 77, Sweden.
Talita YorkInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Asanda Gwashu-NyangiweInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Nonkululeko NdabambiInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Ruwayhida ThebusInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Paula CohenInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Bronwen LambsonNational Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Haajira KaldineNational Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Sinethemba BhebheNational Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Michal JuraskaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Hongjun BaiU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Allan C deCampVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
James LudwigVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Cindy MolitorVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Nicolas BeaumeInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
David MattenInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Yunda HuangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Lily ZhangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Daniel B ReevesVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Bryan MayerVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Shelly T KarunaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
John A HuralVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Lynn MorrisNational Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
David MontefioriDepartment of Surgery, Duke University Medical Center, Durham, NC 27710, US.A.
Roger E BumgarnerDepartments of Microbiology, University of Washington, Seattle, WA, USA.
Penny L MooreCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu Natal, Durban, South Africa.
Paul T EdlefsenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Srilatha EdupugantiEmory University, Atlanta, GA, USA.
Nyaradzo MgodiUniversity of Zimbabwe College of Health Sciences Clinical Trials Research Centre, Harare, Zimbabwe.
M Juliana McElrathVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Myron S CohenDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Lawrence CoreyVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Peter B GilbertVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
James I MullinsDepartments of Microbiology, University of Washington, Seattle, WA, USA.
Funding
LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6MLOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5MLC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6MSDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9MSDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9MLC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2MUZ-UCSF CTUUM1AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZVAVAHERA MIKE CHIRENJE, LYNDA STRANIX-CHIBANDA · 2012 to 2026
$75.9MHIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapyR01AI157854 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI KURITZKES, DANIEL R., TSIBRIS, ATHE M. · 2021 to 2025
$4.0MPhylodynamic mechanisms of HIV reservoir seeding and maintenanceR01AI186721 · NIAID · FRED HUTCHINSON CANCER CENTER · PI Daniel Reeves · 2024 to 2026
$2.6MAntigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan AfricaR01AI152115 · NIAID · UNIVERSITY OF CAPE TOWN · PI GILBERT, PETER B., WILLIAMSON, CAROLYN · 2020 to 2024
$1.7MSimulating persistence and elimination of the HIV reservoirK25AI155224 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI REEVES, DANIEL · 2020 to 2024
$581kGates Foundation INV-016189NIAID NIH HHS K25 AI155224NIAID NIH HHS R01 AI152115NIAID NIH HHS R01 AI157854NIAID NIH HHS R01 AI186721NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI068635NIAID NIH HHS UM1 AI069436
Abstract
In the HIV antibody mediated prevention (AMP) trials, the broadly neutralizing antibody VRC01 demonstrated protective efficacy against new diagnoses with susceptible HIV strains. To understand how VRC01 shaped breakthrough infections, we performed deep sequencing on 172 participants in the placebo and treatment arms, generating 63,444
Indexed as
antibody mediated preventionBiological Sciencesbroadly neutralizing antibodiesdeep sequencingHIVMedical SciencesVRC01
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.